These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33041663)

  • 21. HDAC8 Enhances the Function of HIF-2α by Deacetylating ETS1 to Decrease the Sensitivity of TKIs in ccRCC.
    Qian K; Li W; Ren S; Peng W; Qing B; Liu X; Wei X; Zhu L; Wang Y; Jin X
    Adv Sci (Weinh); 2024 Sep; 11(36):e2401142. PubMed ID: 39073752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation.
    Feng C; Ding G; Jiang H; Ding Q; Wen H
    Tumour Biol; 2015 May; 36(5):3457-64. PubMed ID: 25528216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Downregulation of WDR20 due to loss of 14q is involved in the malignant transformation of clear cell renal cell carcinoma.
    Takahashi M; Tsukamoto Y; Kai T; Tokunaga A; Nakada C; Hijiya N; Uchida T; Daa T; Nomura T; Sato F; Mimata H; Matsuura K; Moriyama M
    Cancer Sci; 2016 Apr; 107(4):417-23. PubMed ID: 26790128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
    Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
    Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
    [No Abstract]   [Full Text] [Related]  

  • 25. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 26. MET Inhibition in Clear Cell Renal Cell Carcinoma.
    Xie Z; Lee YH; Boeke M; Jilaveanu LB; Liu Z; Bottaro DP; Kluger HM; Shuch B
    J Cancer; 2016; 7(10):1205-14. PubMed ID: 27390595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
    Liu W; Ren D; Xiong W; Jin X; Zhu L
    J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy.
    Kammerer-Jacquet SF; Medane S; Bensalah K; Bernhard JC; Yacoub M; Dupuis F; Ravaud A; Verhoest G; Mathieu R; Peyronnet B; Brunot A; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
    Target Oncol; 2017 Aug; 12(4):487-494. PubMed ID: 28550387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
    PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.
    Proskorovsky I; Benedict A; Negrier S; Bargo D; Sandin R; Ramaswamy K; Desai J; Cappelleri JC; Larkin J
    BMC Cancer; 2018 Dec; 18(1):1271. PubMed ID: 30567533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma.
    Song Z; Cao Q; Ruan H; Yang H; Wang K; Bao L; Cheng G; Xu T; Xiao H; Wang C; Liu D; Chen K; Zhang X
    Exp Cell Res; 2018 Nov; 372(2):118-128. PubMed ID: 30267660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma.
    Zhou J; Deng Z; Chen Y; Gao Y; Wu D; Zhu G; Li L; Song W; Wang X; Wu K; He D
    Urol Oncol; 2015 Mar; 33(3):113.e9-17. PubMed ID: 25192834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.
    Randrup Hansen C; Grimm D; Bauer J; Wehland M; Magnusson NE
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma.
    Sakaguchi T; Yoshino H; Sugita S; Miyamoto K; Yonemori M; Osako Y; Meguro-Horike M; Horike SI; Nakagawa M; Enokida H
    Oncotarget; 2018 May; 9(33):23003-23017. PubMed ID: 29796168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclophilin D-mediated apoptosis attributes to sorafenib-induced cytotoxicity in clear cell-renal cell carcinoma.
    Hu W; Yuan Q; Liu XH; Zhu HC; Lv SQ; Wang XH
    Eur J Pharmacol; 2015 Feb; 749():142-50. PubMed ID: 25614335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.
    Tsuzuki T; Sassa N; Shimoyama Y; Morikawa T; Shiroki R; Kuroda M; Fukatsu A; Kuwahara K; Yoshino Y; Hattori R; Gotoh M
    Histopathology; 2014 Mar; 64(4):484-93. PubMed ID: 24274732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
    Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
    Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low neighbor of Brca1 gene expression predicts poor clinical outcome and resistance of sunitinib in clear cell renal cell carcinoma.
    Xiao W; Xiong Z; Yuan C; Bao L; Liu D; Yang X; Li W; Tong J; Qu Y; Liu L; Xiao H; Yang H; Zhang X; Chen K
    Oncotarget; 2017 Nov; 8(55):94819-94833. PubMed ID: 29212269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.
    Liu J; Liu Z; Liu Q; Li L; Fan X; Wen T; An G
    Oncol Rep; 2018 Oct; 40(4):2023-2035. PubMed ID: 30066941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overall tumor genomic instability: an important predictor of recurrence-free survival in patients with localized clear cell renal cell carcinoma.
    Correa AF; Ruth KJ; Al-Saleem T; Pei J; Dulaimi E; Kister D; Collins M; Abbosh PH; Slifker MJ; Ross E; Uzzo RG; Testa JR
    Cancer Biol Ther; 2020 May; 21(5):424-431. PubMed ID: 32116106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.